JOHANN WOLFGANG GOETHE-UNIVERSITAT FRANKFURT AM MAIN
发明人:
ZEHENDNER, CHRISTOPH MICHAEL,DIMMELER, STEFANIE,ZEIHER, ANDREAS
申请号：
CA2980385
公开号：
CA2980385A1
申请日:
2016.03.18
申请国别(地区):
CA
年份:
2016
代理人:
摘要：
The present invention provides novel non-coding RNAs (lncRNA) that were identified to be expressed in pericytes upon hypoxia. The lncRNA of the invention positively affect Platelet-derived Growth Factor Receptor (PDGFR) beta expression, pericytes proliferation and pericyte recruitment to endothelial cells. The invention provides inhibitors of the lncRNA for use in the treatment of diseases mediated by PDGFR expression. For example the invention described antisense approaches to target the lncRNA of the invention. Furthermore, the invention provides lncRNA inhibitors as amplifier of therapeutic PDGFR inhibitors such as imatinib or other tyrosine kinase inhibitors. lncRNA inhibitors and methods for screening modulators of lncRNA expression and/or function are provided.
